High response rate with T-VEC in early metastatic melanoma (Stage IIIB/C-IVM1a)

V. Franke,D.M.S. Berger,W.M.C. Klop,B. van der Hiel,B.A. van de Wiel,S. ter Meulen,M.W.J.M. Wouters,W.J. van Houdt,A.C.J. van Akkooi

Annals of Oncology（2019）

引用 0|浏览15

暂无评分

摘要

Background: Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus, type 1 (HSV-1), which can be administered intralesionally in patients with stage IIIB/C-IVM1a unresectable melanoma (EMA label). The phase 3 OPTiM registration study showed an overall response rate (ORR) of 26%.

查看译文

关键词

early metastatic melanoma,t-vec,c-ivm

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要